ArticleOncoTargets and therapy2021
RPARP-AS1/miR125a-5p Axis Promotes Cell Proliferation, Migration and Invasion in Colon Cancer.
Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- NamiRNA-Enhancer Network: The Changing Era Challenge and Chance of miRNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- LncRNA HAND2-AS1 Inhibited Colon Cancer Progression By Regulating miR-3118/ZG16 Axis.Biochemical genetics · 2025Article
- Deciphering the role of cuproptosis-related lncRNAs in shaping the lung cancer immune microenvironment: A comprehensive prognostic model.Journal of cellular and molecular medicine · 2024Article
- High expression of NXPH4 correlates with poor prognosis, metabolic reprogramming, and immune infiltration in colon adenocarcinoma.Journal of gastrointestinal oncology · 2024Article
- LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism.BMC cancer · 2024Article
- Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.BMC medical genomics · 2023Article
- PVT1 inhibition stimulates anti-tumor immunity, prevents metastasis, and depletes cancer stem cells in squamous cell carcinoma.Cell death & disease · 2023Article
- Modulation of hepatic stellate cells by MutaflorJournal of translational medicine · 2022Article
- Bioinformatics analysis of lncRNAs in the occurrence and development of osteosarcoma.Translational pediatrics · 2022Article
- A two-phase comprehensive NSCLC prognostic study identifies lncRNAs with significant main effect and interaction.Molecular genetics and genomics : MGG · 2022Article
- Article
- The m7G-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Tumour Immune Infiltration in Colon Cancer.Frontiers in genetics · 2022Article
- Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt was reported that long-noncoding RNAs (lncRNAs) had been identified as a novel class of regulators related to various cancers. RPARP-AS1, a differentially-expressed gene, was found in analysis of the gene expression profile of CRC from GEO database. However, its function has not been clear.
methodsRPARP-AS1 expression was determined by qPCR and Startbase3 analysis. Knockdown of RPARP-AS1 in CRC cell lines was performed by RNAi technology, named si-RPARP-AS1 HCT116 and si-RPARP-AS1 LoVo. Cell proliferation was examined by CCK8 and colony formation assay. RNA pull-down and Luciferase reporter assay were performed to confirm the interaction between RPARP-AS1 and miR-125a-5p.
resultsIn the study, we found that the expression of RPARP-AS1 was significantly up-regulated in CRC tissues and multiple CRC cell lines, which was closely related to poor prognosis of CRC patients. Loss-of-function studies indicated that knockdown of RPARP-AS1 inhibited CRC cell proliferation, migration and invasion in HCT116 and LoVo cell lines. Results of research on the mechanisms showed that RPARP-AS1 functioned as a competitive endogenous RNA (ceRNA) to sponge miR-125a-5p, therefore promoting CRC procession.
conclusionIn summary, these results indicated that RPARP-AS1/miR-125a-5p axis played a positive role in promoting cell proliferation, migration and invasion in CC. It may be as a biomarker used to evaluate CRC prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.